Dasatinib News and Research

RSS
Dasatinib is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.
Study shows targeted therapeutic after chemotherapy kills transitional cancer cells

Study shows targeted therapeutic after chemotherapy kills transitional cancer cells

PF-114 shows promise in therapy-resistant CML, Ph-positive ALL

PF-114 shows promise in therapy-resistant CML, Ph-positive ALL

Ponatinib ‘superior’ to sequential second-generation TKI treatment in CML

Ponatinib ‘superior’ to sequential second-generation TKI treatment in CML

Rapamycin and dasatinib combination may be beneficial in treating breast cancer, say scientists

Rapamycin and dasatinib combination may be beneficial in treating breast cancer, say scientists

EMA's CHMP adopts final opinion on ARIAD Pharmaceuticals' Iclusig (ponatinib)

EMA's CHMP adopts final opinion on ARIAD Pharmaceuticals' Iclusig (ponatinib)

Dasatinib: Leukemia drug shows promise for treating skin, breast and other cancers

Dasatinib: Leukemia drug shows promise for treating skin, breast and other cancers

Avillion initiates BOSULIF Phase 3 trial in patients with chronic phase Ph+ CML

Avillion initiates BOSULIF Phase 3 trial in patients with chronic phase Ph+ CML

Co-targeting strategies suggested for EGFR-TKI resistance in NSCLC

Co-targeting strategies suggested for EGFR-TKI resistance in NSCLC

Head and neck cancers associated with genetic alterations could be sensitive to existing cancer drug

Head and neck cancers associated with genetic alterations could be sensitive to existing cancer drug

FDA grants full approval of SYNRIBO for injection

FDA grants full approval of SYNRIBO for injection

Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia

Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia

Dasatinib+letrozole improves survival for women with hormone receptor-positive, HER2-negative metastatic breast cancer

Dasatinib+letrozole improves survival for women with hormone receptor-positive, HER2-negative metastatic breast cancer

Advanced genetics technologies may help predict patient outcomes in people with ALL

Advanced genetics technologies may help predict patient outcomes in people with ALL

ARIAD Pharmaceuticals' Iclusig gets EC marketing authorization for CML and Ph+ ALL treatment

ARIAD Pharmaceuticals' Iclusig gets EC marketing authorization for CML and Ph+ ALL treatment

Nano-biosensors along with new  imaging techniques can improve drug targeting in pancreatic cancer

Nano-biosensors along with new imaging techniques can improve drug targeting in pancreatic cancer

Chronic myeloid leukemia patients treated with tyrosine kinase inhibitors have quality-of-life issues

Chronic myeloid leukemia patients treated with tyrosine kinase inhibitors have quality-of-life issues

European Commission grants conditional marketing authorization for Pfizer's BOSULIF

European Commission grants conditional marketing authorization for Pfizer's BOSULIF

Researchers complete phase II clinical trial of dasatinib for patients with higher-risk MDS

Researchers complete phase II clinical trial of dasatinib for patients with higher-risk MDS

Memorial Sloan-Kettering scientist wins Breakthrough Prize in Life Sciences

Memorial Sloan-Kettering scientist wins Breakthrough Prize in Life Sciences

Pairing Avastin with dasatinib can stop lethal spread of glioblastoma multiforme

Pairing Avastin with dasatinib can stop lethal spread of glioblastoma multiforme